Ted Broman

Vice President, Chemistry, Manufacturing and Control

Mr. Broman has been Vice President, Chemistry, Manufacturing and Control since February 2009. Mr. Broman joined VIVUS in January 2006 as Senior Director, Chemistry, Manufacturing, and Control. Prior to joining VIVUS, Mr. Broman was Executive Director, Project Management at Durect, Inc. from 2001 to 2005. From 1994 to 2001, Mr. Broman held Senior Management positions in Operation and Project Management at Matrix Pharmaceutical, Inc. From 1988 to 1994 he was Director, Analytical Services at Cygnus, Inc. and from 1976 to 1988, Mr. Broman served in several positions in Syntex Laboratories, Syntex Chemicals Group, Corporate Quality Assurance, and Corporate Technical Services. Mr. Broman has a B.A. in Biochemistry and Molecular Biology from the University of California, Santa Barbara.


Wesley W. Day, Ph.D.

Vice President, Clinical Development

Dr. Day has been the Vice President of Clinical Development since November 2005. Prior to joining VIVUS, Dr. Day held a variety of positions with Pfizer, Inc. from 1993 until his departure in October 2005. Most recently, Dr. Day was the Senior Director, Safety Risk Management from September 2003 until his departure. Prior to this position, Dr. Day served as the Senior Associate Director, Worldwide Regulatory Affairs from August 2001 to 2003, Associate Director II, Worldwide Regulatory Affairs from 2000 to 2001, Associate Director I, Clinical Development from 1999 to 2000, Senior Clinical Research Investigator from 1997 to 1998, Senior Research Scientist from 1995 to 1997 and Research Scientist from 1993 to 1994. Dr. Day holds a Ph.D. in Pharmacology and Toxicology from the University of Maryland at Baltimore, a B.S. with Highest Honors from the University of Texas at Pan American. Dr. Day is an Adjunct Associate Professor for the School of Pharmacy at the University of Maryland at Baltimore where he has held an Adjunct Appointment since 1995. He has also been an Adjunct Assistant Professor for Temple University.


Seth H.Z. Fischer

Chief Executive Officer

Seth H.Z. Fischer has served as Chief Executive Officer and a Director since September 3, 2013. He is currently a member of the Board of Directors of Trius Therapeutics, Inc. and BioSig Technologies, Inc, and an advisor to MedHab, LLC. Mr. Fischer served in positions of increasing responsibility with Johnson & Johnson from 1983 until his retirement in 2012. Most recently, Mr. Fischer served as Company Group Chairman Johnson & Johnson and Worldwide Franchise Chairman, Cordis Corporation from 2008 to 2012, and as Company Group Chairman, North America Pharmaceuticals from 2004 to 2007, which included responsibilities for Ortho-McNeil Pharmaceuticals, Janssen and Scios. Prior to that, Mr. Fischer served as President of Ortho-McNeil Pharmaceuticals from 2000 to 2004. His operating responsibilities encompassed the commercialization of products in multiple therapeutic categories including Topamax® for epilepsy and migraine and products in the analgesic, anti-infective, cardiovascular, neurologic, psychiatric and women's health areas. Mr. Fischer earned a Bachelor of General Studies from Ohio University and served as a captain in the U.S. Air Force.

Johann Noor Mohamed

Interim Chief Finance Officer and Interim Chief Accounting Officer

Mr. Noor Mohamed, age 43, has served as interim Chief Finance Officer and interim Chief Accounting Officer since October 1, 2015. Prior to that he served as the Company’s Vice President and Corporate Controller from June 2015 to September 2015, as the Company’s Corporate Controller from January 2014 to May 2015 and as the Company’s Assistant Controller from October 2012 to December 2013. Prior to his employment with the Company, Mr. Noor Mohamed was the Global Controller at Molecular Devices, LLC, a supplier of high-performance bioanalytical measurement systems, from July 2011 to September 2012. Prior to this, Mr. Noor Mohamed was the Director of Finance at Actel Corporation, now Microsemi Corporation, a provider of semiconductor solutions, from June 2006 to July 2011. Mr. Noor Mohamed began his career with Ernst & Young, a public accounting firm, where he earned his license as a certified public accountant. Mr. Noor Mohamed received his accounting qualification from the Association of Chartered Certified Accountants, Glasgow, United Kingdom and holds a Master of Business Administration degree from Babson College, Wellesley, MA.


John L. Slebir, Esq.

Senior Vice President Business Development and General Counsel

John L. Slebir, Esq. joined VIVUS in September 2009. Since January 2014, Mr. Slebir has served as our Senior Vice President, Business Development and General Counsel, and, since June 2012, he also has served as our Secretary. From June 2011 until January 2014, Mr. Slebir served as our Vice President, Business Development and General Counsel, from January 2011 until June 2011, he served as our Vice President, General Counsel, and, from September 2009 until January 2011, he served as our General Counsel on a part-time basis. From March 1999 to January 2011, Mr. Slebir served as an attorney at Wilson Sonsini Goodrich & Rosati, P.C., specializing in corporate securities and corporate governance. Prior to joining Wilson Sonsini Goodrich & Rosati, P.C., Mr. Slebir was an attorney at two prominent Bay Area law firms specialized in insurance defense litigation. Mr. Slebir holds a B.A. in Communications from San Diego State University and a J.D. from Santa Clara University School of Law.


Santosh T. Varghese, MD

Vice President, Medical & Regulatory Affairs, Pharmacovigilance, and QA

Dr. Varghese has been the company's Vice President, Medical & Regulatory Affairs, Pharmacovigilance, and QA since October 2013. He joined the company in March 2012 as Vice President, Head of Medical Affairs. Prior to joining the company, Dr. Varghese was Senior Vice President, Medical Affairs at Élan Pharmaceuticals where he lead Medical Affairs teams responsible for the BioNeurology portfolio. He held the position of Vice President Primary Care & Cardiovascular in Global Medical Affairs at Schering-Plough/Merck, and also held senior roles at Aventis/Sanofi-Aventis where he contributed to both US and global brand strategy and tactics. Dr. Varghese has served on the Board of Directors of the American Lung Association - New York, and was on faculty at Touro University College of Medicine. Dr. Varghese earned his M.D. from St. George's University School of Medicine, and B.S. in Biology from Pennsylvania State University. He completed his medical training in the Caribbean, United States, and United Kingdom.

Sandra E. Wells, Ph.D.

Vice President, Patents and Assistant General Counsel

Dr. Wells has been Vice President, Patents and Assistant General Counsel since January 2014. From June 2012 to December 2013, Dr. Wells served as the Senior Director of Legal Affairs. Prior to joining VIVUS, Dr. Wells was in-house counsel at Affymetrix, Inc. from 2002 to 2012, serving as Vice President and Chief Intellectual Property Counsel from 2008 to 2012. In this role she was responsible for overseeing the company’s patent and trademark portfolios and managing patent litigation. Dr. Wells received her B.A. in biology from Whitman College, her Ph.D. in Molecular Biology from U.C. Santa Cruz and completed postdoctoral studies in the department of Molecular and Cellular Biology at U.C. Berkeley where she was a Jane Coffin Childs Fellow. She received her J.D. from Santa Clara University School of Law and has been admitted to practice in California and before the U.S. Patent and Trademark Office.